Lennox-gastaut Syndrome
📧 Sign up to get email alerts when something new happens for Lennox-gastaut Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-03-11Clinical Trial Update: A Long Term Extension Study of E2080 in Lennox-Gastaut Patients [Phase 3]
Phase 3 long-term extension study of E2080 in Lennox-Gastaut syndrome completed with results posted.
-
FDA approval · 2019-01-30FDA Approved: CLOBAZAM — Original Application (Micro Labs Limited)
The FDA approved Micro Labs Limited's generic CLOBAZAM (clobazam) under Original Application ANDA211711.
-
FDA approval · 2018-12-12FDA Approved: EPIDIOLEX — Supplemental Application (Jazz Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Epidiolex (cannabidiol) submitted by Jazz Pharmaceuticals, Inc. The action updates the produ…
-
FDA approval · 2018-11-01FDA Approved: SYMPAZAN — Original Application (Aquestive Therapeutics)
The FDA approved SYMPAZAN (clobazam) via an Original Application from Aquestive Therapeutics.
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved an original ANDA for CLOBAZAM from Amneal Pharmaceuticals NY LLC, authorizing the generic version of clobazam.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved the original application for CLOBAZAM (clobazam) from Upsher-Smith Laboratories, LLC, as a generic anticonvulsant product. The …
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals' original ANDA for CLOBAZAM (clobazam), enabling the generic version of the epilepsy medication to b…
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approved CLOBAZAM (clobazam) through an Original Abbreviated New Drug Application for Taro Pharmaceuticals U.S.A., Inc., representing a …
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' generic clobazam (CLOBAZAM) under an original ANDA.
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Bionpharma Inc.)
FDA approves CLOBAZAM as a generic clobazam product via an Original Application (ANDA) for Bionpharma Inc.; submission status is AP.
-
CLINICAL_TRIALS trial_result · 2018-07-27Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults [Phase 3]
Phase 3 clinical trial evaluating CBD as adjunctive treatment for seizures in Lennox-Gastaut syndrome; trial completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2018-07-27Clinical Trial Update: Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults [Phase 3]
Phase 3 trial update on GWP42003-P for seizures in Lennox-Gastaut syndrome, reporting efficacy and safety results.
-
FDA approval · 2018-06-25FDA Approved: EPIDIOLEX — Original Application (Jazz Pharmaceuticals, Inc.)
FDA approved Epidiolex (cannabidiol) under its original application for treating seizures in Lennox-Gastaut syndrome and Dravet syndrome. Th…
-
FDA approval · 2018-06-15FDA Approved: ONFI — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for ONFI (clobazam) submitted by Lundbeck Pharmaceuticals LLC. The approval updates the drug's l…
-
FDA approval · 2018-06-15FDA Approved: ONFI — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA has approved a supplemental application for ONFI (clobazam) submitted by Lundbeck Pharmaceuticals LLC.
-
CLINICAL_TRIALS withdrawal · 2018-04-30Clinical Trial Update: Turmeric as Treatment in Epilepsy [NA]
A clinical trial evaluating turmeric as a treatment for epilepsy has been withdrawn, including conditions such as Dravet syndrome, Lennox-Ga…
-
CLINICAL_TRIALS withdrawal · 2018-01-04Clinical Trial Update: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome [Phase 3]
A Phase 3 trial of cannabidiol oral solution as adjunctive therapy for Lennox-Gastaut Syndrome was withdrawn.
-
FDA approval · 2017-06-16FDA Approved: FELBAMATE — Original Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approved the original application for Felbamate, authorizing its generic marketing in the United States by Taro Pharmaceuticals U.S.A., …
-
FDA approval · 2017-05-30FDA Approved: FELBAMATE — Original Application (Zydus Lifesciences Limited)
FDA approved Felbamate from Zydus Lifesciences Limited under an Original Application (ANDA).
-
FDA approval · 2016-12-16FDA Approved: ONFI — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for ONFI (clobazam) from Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2016-12-16FDA Approved: ONFI — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for ONFI (clobazam) from Lundbeck Pharmaceuticals LLC, expanding the label for seizures associated w…
-
CLINICAL_TRIALS research · 2016-10-11Clinical Trial Update: Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome [EARLY_Phase 1]
This document provides an update on an early Phase 1 clinical trial evaluating vagus nerve stimulation therapy in children with Lennox-Gasta…
-
CLINICAL_TRIALS trial_result · 2016-06-29Clinical Trial Update: Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study [Phase 4]
Phase 4 pilot study evaluating transcranial direct current stimulation for treatment-resistant Lennox-Gastaut syndrome in children has compl…
-
FDA label_change · 2016-06-16FDA Approved: ONFI — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for ONFI (clobazam) submitted by Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2016-05-16FDA Approved: RUFINAMIDE — Original Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved Glenmark's original application for Rufinamide, providing a generic version of the anticonvulsant. Rufinamide is indicated as a…